Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 258

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 258
---
 31, 2025, the Company’s
Board approved certain amendments to its Share Incentive Plan of 2024, the awards of which are valid for a period of 10 years from March
28, 2025, whereby the maximum aggregate number of shares with respect to which Awards may be granted under the Plan shall be 1,054,260
Shares, which may be increased from time to time as determined by the Board or Committee of the Board, in an amount equal to 20% of the
then outstanding ordinary shares of the Company at the time of such increase. Shares may be made available from Shares held in treasury
or authorized but unissued shares of the Company not reserved for any other purpose. To date, no shares have been awarded under this
Plan.

On April 1, 2025, the Company
entered into a new Securities Purchase Agreement (“2025 Securities Purchase Agreement”) with JAK, pursuant to which, amongst
other things: (i) the Company agreed to sell, at an initial closing, a senior convertible note in the aggregate original principal amount
not exceeding $3,200,000, convertible into Class A Ordinary Shares pursuant to its terms; and (ii) the Company may require JAK (or JAK
may require the Company, as applicable) to participate in the sale of one or more additional convertible notes (which aggregate original
principal amount for all additional convertible notes shall not exceed $25,600,000).

The 2025 Securities Purchase
Agreement is filed as Exhibit 4.1 of the Company’s current report on Form 6-K dated April 3, 2025 and is incorporated by reference
herein. The first tranche of $3,200,000 was received on June 3, 2025.

On April 2, 2025, the Company
consummated the fourth tranche of its debt financing under the terms of its existing Securities Purchase Agreement with the investor,
At the closing of the fourth tranche, the Company sold to the investor a senior convertible note in the principal amount of $2,000,000.
The Note bears an interest rate of 14.75% per annum and may be adjustable from time to time pursuant to its terms. The funding from these
arrangements with the investor is intended to be used to finance the establishment of a fertility clinic in Dubai.

Mr. Yip Eng Jeremy Foo, a
director of NewGenIvf Group Limited (the “